(23) retrospectively analyzed the correlation between the molecular characteristics of 48 patients in the clinical trial of ACOSOG Z1041 and the efficacy of trastuzumab combined with chemotherapy, i.e., neoadjuvant therapy, for breast cancer and found that 2 patients with ERBB2 fusions (ERBB2 (exon19)-IKZF3, ERBB2 (exon1)-TBC1D3P1-DHX40P1) did not achieve pathologic complete response (pCR). This evidence concerns the gene IKZF3 and breast carcinoma.